Category: pyrazoles-derivatives

On November 26, 2020, Bandiera, Tiziano; Bertozzi, Fabio; Di Fruscia, Paolo; Sorana, Federico; Berti, Francesco; Rodriguez Gimeno, Alejandra; Caci, Emanuela; Ferrera, Loretta; Pedemonte, Nicoletta; Vicente Galietta, Luis Juan published a patent.Synthetic Route of 1186608-73-0 The title of the patent was Preparation of pyrazolopyridines and related heterocycles and compositions containing them for the treatment of cystic fibrosis. And the patent contained the following:

The invention relates to preparation of pyrazolopyridines and related heterocycles of formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds I and their uses, in particular to modulate CFTR protein or ABC protein activities. Compounds I wherein R1 is H; Z is CO or SO2; X1-X4 each independently is CRVII and N, with the proviso that the number of nitrogen atoms in the ring is comprised from O to 2; R2 is H, OH, NO, etc.; A1-A4 each independently is O, SO2, CO, etc.; B represents an unsubstituted or a substituted aromatic or heteroaromatic ring; n and m are each independently selected from the group consisting of O, 1, 2; etc., are claimed. The example compound II was prepared using 3-hydrazinobenzoic acid as starting material (procedure given). Compounds I were evaluated for their biol. activity (data given). Compounds I and pharmaceutical composition comprising them, are modulators of CFTR protein or ABC protein activities, and can be used in treatment of cystic fibrosis and other diseases. The experimental process involved the reaction of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine(cas: 1186608-73-0).Synthetic Route of 1186608-73-0

The Article related to pyrazolopyridine preparation cftr modulator abc protein cystic fibrosis treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Synthetic Route of 1186608-73-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On November 26, 2021, Yang, Anyue; Ji, Sen; Wang, Hao; Zhang, Dewei; Wang, Xiao; Wang, Zhi; Shen, Huan; Li, Zhiyong; Qian, Xinying published a patent.Application In Synthesis of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol The title of the patent was Transforming growth factor receptor antagonist for treating diseases mediated by TGF-β overexpression and preparation method thereof. And the patent contained the following:

The invention relates to the transforming growth factor receptor antagonists with general formula I for treating diseases mediated by TGF-β overexpression and the preparation method thereof [where L1=O, NH; L2=absent or NH; R1=absent or five membered heteroaromatic ring; R2=ethyl, tert Bu, tetrahydropyran-4-yl, tetrahydrofuran-3-yl, cyclopropyl or cyclobutyl; R3=cyclopropyl, Et, iso-Pr, CHF2, CH2CHF2, CH2CF3; R4=F, Cl, H; X1, X2, X3=CH, N; X4=N, -CRa, where Ra=H, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl and hydroxyl substituted alkynyl, hydroxyl substituted alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C3-C6 heterocyclic], which has the use of treating and/or preventing a variety of diseases mediated by ALK5. For example, compound2-(4-((4-((3-cyclopropyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-5-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propyl-2-ol was prepared by multi-step reaction with tetrahydro-4H-pyran-4-one, tert-Bu carbazate, Et 3-cyclopropyl-3-oxopropionate, 2-chloro-4-fluoropyridine and 2-(4-aminopyridin-2-yl)propan-2-ol. The title compound can be used to prepare drugs for treating diseases mediated by TGF-β overexpression. The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Application In Synthesis of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol

The Article related to transforming growth factor beta overexpression receptor antagonist preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Application In Synthesis of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On December 31, 2012, Zheng, Chang-Ji; Xu, Li-Li; Sun, Liang-Peng; Miao, Jing; Piao, Hu-Ri published an article.Application In Synthesis of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde The title of the article was Synthesis and antibacterial activity of novel 1,3-diphenyl-1H-pyrazoles functionalized with phenylalanine-derived rhodanines. And the article contained the following:

In the present study, a series of novel 1,3-diphenyl-1H-pyrazoles functionalized with phenylalanine-derived rhodanine derivatives were synthesized and evaluated for their antibacterial activity. Several of these compounds, e.g. I, exhibited stronger activity than the standard drugs, norfloxacin and oxacillin, with MIC values of 1 μg/mL against methicillin-resistant Staphylococcus aureus and quinolone-resistant S. aureus. None of the compounds showed any activity against Gram-neg. bacteria. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Application In Synthesis of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

The Article related to pyrazole diphenyl phenylalanine rhodanine preparation antibacterial activity, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Application In Synthesis of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On October 15, 2014, Yao, Qingjia; Wu, Simin; Xu, Yangjun published a patent.Electric Literature of 924909-16-0 The title of the patent was A process for preparing 4-chloro-1H-pyrazolo[3,4-b]pyridin-3-amine. And the patent contained the following:

The invention relates to a process for the preparation of 4-chloro-1H-pyrazolo[3,4-b]pyridin-3-amine via heterocyclization of 2-propenenitrile with 4-methoxybenzaldehyde followed by reaction with tri-Et orthoformate and 2,2-dimethyl-1,3-dioxane-4,6-dion, heterocyclization, chlorination, deprotection, nitration, and reduction The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Electric Literature of 924909-16-0

The Article related to chloropyrazolopyridinamine preparation mannich heterocyclization nitration, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Electric Literature of 924909-16-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On February 15, 2007, Ozawa, Sawako; Oikawa, Nobuhiro; Mizuguchi, Eisaku; Ebiike, Hirosato; Watanabe, Fumio; Morikami, Kenji; Shimma, Nobuo; Ishii, Nobuya; Tsukaguchi, Toshiyuki; Tamaki, Yasuhiro; Takahashi, Hidenori published a patent.Synthetic Route of 924909-16-0 The title of the patent was Preparation of urea derivatives as multi kinase inhibitors. And the patent contained the following:

The title compounds I [wherein Ar = (un)substituted Ph or naphthyl; T = alkyl, alkoxy, etc.; X = O, CH2, CO, etc.; Y = CH or N; R2-R4 = independently H, (un)substituted alkyl, etc.], or pharmaceutically acceptable salts or prodrugs thereof are prepared as multi kinase inhibitors. For example, the compound II was prepared in a multi-step synthesis. Some of compounds I showed good inhibitory activities against human cancer cell growth. The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Synthetic Route of 924909-16-0

The Article related to phenyl indole pyrrazolo pyridine urea kinase inhibitor preparation human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Synthetic Route of 924909-16-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 11, 2009, Ahrendt, Kateri A.; Buckmelter, Alexandre J.; De Meese, Jason; Grina, Jonas; Hansen, Joshua D.; Laird, Ellen R.; Lunghofer, Paul; Moreno, David; Newhouse, Brad; Ren, Li; Seo, Jeongbeob; Tian, Hongqi; Wenglowsky, Steven Mark; Feng, Bainian; Gunzner, Janet; Malesky, Kim; Mathieu, Simon; Rudolph, Joachim; Wen, Zhaoyang; Young, Wendy B. published a patent.Reference of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine The title of the patent was N-Pyrazolo[3,4-b]pyridinyl benzamide derivatives as Raf inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Compounds of formula I are useful for inhibition of Raf kinases. Methods of using compounds of formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo prevention or treatment of Raf-mediated disorders in mammalian cells, or associated pathol. conditions are disclosed. Compounds of formula I wherein R1 and R2 are independently H, halo, CN, C1-3 alkyl and C1-3 alkoxy; R3 is H, halo and C1-3 alkyl; R4 is C3-5 cycloalkyl, C1-6 alkyl, C2-6 alkenyl, etc.; R5 is H, halo, CN, NH2 and derivatives, etc.; and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by cyclization of 1H-pyrazol-5-amine with 2-bromomalonaldehyde; the resulting 5-bromo-1H-pyrazolo[3,4-b]pyridine underwent alkylation with 2-(trimethylsilyl)ethoxymethyl chloride to give 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridine, which underwent cross-coupling with tert-Bu carbamate to give tert-Bu 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridin-5-ylcarbamate, which underwent hydrolysis to give 1H-pyrazolo[3,4-b]pyridin-5-amine, which underwent amidation with 2.6-difluoro-3-(propylsulfonamido)benzoic acid to give compound II. All the invention compounds were evaluated for their Raf inhibitory activity. From the assay, it was determined that compound II along with the other example compound exhibited IC50 values of less than 1 μM. The experimental process involved the reaction of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine(cas: 1186608-73-0).Reference of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine

The Article related to pyrazolopyridinyl benzamide preparation raf inhibitor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Reference of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On April 14, 2014, Vignaroli, Giulia; Mencarelli, Martina; Sementa, Deborah; Crespan, Emmanuele; Kissova, Miroslava; Maga, Giovanni; Schenone, Silvia; Radi, Marco; Botta, Maurizio published an article.Name: 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine The title of the article was Exploring the Chemical Space around the Privileged Pyrazolo[3,4-d]pyrimidine Scaffold: Toward Novel Allosteric Inhibitors of T315I-Mutated Abl. And the article contained the following:

A library of pyrazolo[3,4-d]pyrimidines, endowed with a high level of mol. diversity, has been developed applying a synthetic sequence that allowed C3, N1, C4, and C6 substitution. The enzymic screening of this “privileged scaffold”-based compound collection, validated the use of a diversity-oriented approach in a field characteristically explored by target-oriented synthesis. In fact, several compounds showed high activity against the selected kinases (i.e., Src, Abl wt, and T315I mutated-form), furthermore and interestingly a new compound has emerged as an allosteric inhibitor of the T315I mutated-form of Abl, opening up new opportunities for the development of a novel class of noncompetitive inhibitors of Abl (T315I). The experimental process involved the reaction of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine(cas: 85426-79-5).Name: 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine

The Article related to diversity oriented synthesis library pyrazolopyrimidine inhibitor src abl kinase, Enzymes: Substrates-Cofactors-Inhibitors-Activators-Coenzymes-Products and other aspects.Name: 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On April 28, 2022, Lanier, Marion; Boehm, Marcus; Huang, Liming; Martinborough, Esther; Sainz, Marcos; Selfridge, Brandon; Yeager, Adam published a patent.Application of 1014631-89-0 The title of the patent was Modulators of mas-related g-protein receptor x2 and related products and their use. And the patent contained the following:

Methods are provided for modulating MRGPRX2 or a MRGPRX2 ortholog generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, resp., an effective amount of a compound having structure I: or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided. The experimental process involved the reaction of 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid(cas: 1014631-89-0).Application of 1014631-89-0

The Article related to mrgppx2 modulator preparation treatment disease, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Application of 1014631-89-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On March 31, 2022, Lanier, Marion; Boehm, Marcus; Huang, Liming; Martinborough, Esther; Sainz, Marcos; Selfridge, Brandon; Yeager, Adam published a patent.Computed Properties of 1014631-89-0 The title of the patent was Preparation of modulators of MAS-related G-protein receptor X2 and related products and methods. And the patent contained the following:

Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need thereof, resp., an effective amount of a compound of formula I and pharmaceutically acceptable salts, isomers, hydrates, solvates and isotopes thereof. Compounds of formula I, wherein R1 is cycloalkyl, aryl, heterocyclyl;, R2, R3, R4, R5, R6 are independently H, aryl, cycloalkyl, heteroaryl, heterocyclyl, etc.; each Rx is independently H, aryl, CN, etc.; W is N and CR7 and Z is N and CR8; R7 and R8 are independently H, aryl, cycloalkyl, heteroaryl, etc.; and pharmaceutically acceptable salts, isomers, hydrates, solvates and isotopes thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their MRGPR X2 modulatory activity (some data given). The experimental process involved the reaction of 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid(cas: 1014631-89-0).Computed Properties of 1014631-89-0

The Article related to quinoline preparation mrgpr2 x2 modulator, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Computed Properties of 1014631-89-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On May 15, 2019, Sun, Liangpeng; Wang, Peipei; Xu, Lili; Gao, Lixin; Li, Jia; Piao, Huri published an article.SDS of cas: 36640-53-6 The title of the article was Discovery of 1,3-diphenyl-1H-pyrazole derivatives containing rhodanine-3-alkanoic acid groups as potential PTP1B inhibitors. And the article contained the following:

Two series of 1,3-diphenyl-1H-pyrazole derivatives containing rhodanine-3-alkanoic acid groups were identified as competitive protein tyrosine phosphatase 1B (PTP1B) inhibitors. Among the compounds studied, IIIv was found to have the best in vitro inhibition activity against PTP1B (IC50 = 0.67 ± 0.09 μM) and the best selectivity (9-fold) between PTP1B and T-cell protein tyrosine phosphatase (TCPTP). Mol. docking studies demonstrated that compounds IIIm, IIIv and IVg could occupy simultaneously at both the catalytic site and the adjacent pTyr binding site. These results provide novel lead compounds for the design of inhibitors of PTP1B as well as other PTPs. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).SDS of cas: 36640-53-6

The Article related to inhibition activity ptp1b inhibitor sar mol docking, 1,3-diphenyl-1h-pyrazole, ptp1b inhibitor, rhodanine-3-alkanoic acid, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.SDS of cas: 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics